stockrowModerna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.
- Revenue
- +2.11%
- EPS
- +7.51%
- Free cash flow
- +38.9%
- Total debt
- +1,765.6%
Quarter to June 2026, against a year earlier
Follow MRNA
Alert me
Moderna, Inc. (MRNA) Operating cash flow
Moderna, Inc.'s operating cash flow for fiscal 2025 was −$1.9B, compared with −$3.0B in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.1B. Over the past ten years it has ranged from −$3.1B (fiscal 2023) to $13.6B (fiscal 2021); the current reading is higher than 30% of that period. Moderna, Inc. ranks 602nd of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$1.9B | — |
| FY2024 | −$3.0B | — |
| FY2023 | −$3.1B | — |
| FY2022 | $5.0B | (63.43%) |
| FY2021 | $13.6B | 571.93% |
| FY2020 | $2.0B | — |
| FY2019 | −$459.0M | — |
| FY2018 | −$330.9M | — |
| FY2017 | −$331.5M | — |
| FY2016 | $66.7M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$526.0M | — |
| Mar 2026 | −$630.0M | — |
| Dec 2025 | $930.0M | — |
| Sep 2025 | −$847.0M | — |
| 32 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $4.8B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $3.7B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ARGX argenex SE compare | $1.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.6B |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
| MRNA Moderna, Inc. | −$1.1B |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on MRNA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement